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Abstract: Acinetobacter baumannii plays an increasing role in the pathogenesis of infections in humans. The bacilli are
frequently isolated from patients treated in intensive care units. A growing resistance to antibiotics is leading to the
emergence of strains that are multidrug-resistant and resistant to all available agents. The objective of this study was to
assess susceptibility to antibiotics and to determine the presence and current level of the extended-spectrum b-lacta-
mases (ESBLs) and attempt to isolate the Acinetobacter baumannii strain carrying the blaPER gene. A total of 51 strains of
A. baumannii identified by phenotypic features were examined. That the strains belonged to the species was confirmed
by the presence of the blaOXA-51-like gene. A broth microdilution method was used for antibacterial susceptibility testing.
The occurrence of ESBLs was determined using phenotypic double-disk synergy tests. The PCR technique was used to
confirm the presence of the blaPER-1 gene encoding ESBL. The most active antibiotics were meropenem, cefepime and
ampicillin/sulbactam, with susceptibility shown by 76.5%, 60.8% and 56.9% of the strains, respectively. The strains
exhibited the highest resistance (> 75%) to piperacillin, tetracycline, ciprofloxacin and cefotaxime. Phenotypic tests
revealed ESBL mechanism of resistance in approximately 20% of Acinetobacter baumannii isolates. However, the PCR
technique did not confirm the presence of the blaPER-1 gene in any of the Acinetobacter baumannii strains examined in our
hospital. Acinetobacter baumannii strains demonstrate considerable resistance to many groups of antibiotics. Our find-
ings indicate the involvement of enzymes belonging to families other than PER b-lactamase in resistance to b-lactams in
A. baumannii. (Folia Histochemica et Cytobiologica 2012; Vol. 50, No. 1, pp. 46–51)
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Introduction
In recent decades, Acinetobacter baumannii has be-
come more prevalent as an opportunistic pathogen,
especially as a multi-drug resistant agent (MDR) us-
ing different mechanisms of resistance [1–3]. b-lacta-
mases have the essential participation in the resistance
to b-lactams. Acinetobacter baumannii strains produc-
ing PER-1 b-lactamase have been described in Tur-
key, Korea and France [4–6].
The objective of this study was to isolate Acineto-
bacter baumannii strains producing the PER family
extended spectrum b-lactamase in patients from the
north eastern of Poland, and to assess their suscepti-
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bility to antibiotics, with the determination of resis-
tance phenotypes. Until now, the occurrence of this
enzyme in Acinetobacter baumannii strains in Poland
has not been reported.
The PER-1 extended spectrum b-lactamase rep-
resents class A b-lactamases classified according to
the scheme of Ambler. The enzyme is weakly related
to other extended spectrum b-lactamases [7]. It con-
ditions resistance to penicillin, cefotaxime, ceftazi-
dime and aztreonam, and its activity is well inhibited
by clavulanic acid, sulbactam and tazobactam [7, 8].
Currently, there are seven ESBL variants in the PER
family [9]. PER-1 was first identified in 1993 in
a P. aeruginosa strain isolated from a Turkish patient
in France [7]. The strains have also been found in Bel-
gium [10] and Italy [11].
Material and methods
Bacterial strains. The study material consisted of 51 Acine-
tobacter baumannii strains isolated from clinical samples
obtained from patients treated in departments of the Uni-
versity Hospital in Bialystok. The bacteria were identified
by the VITEK 2 GN card and the automatic system VITEK 2
(bioMerieux, Durham, NC, USA) according to the manu-
facturer’s instructions. Additionally, advantage was taken
of the ability of Acinetobacter baumannii to grow at a tem-
perature of 44°C and of the presence of blaOXA-51-like carbap-
enemase genes that are naturally found in this species [12].
Detection of b-lactamases. The detection of extended spec-
trum b-lactamases was performed using a standard double-
disk synergy test (DDST) [13], with disks containing ceftazi-
dime, cefotaxime and additionally aztreonam and cefepime
[14]. They were tested simultaneously on two media: (1)
Mueller–Hinton agar (Oxoid Ltd, Basingstoke, UK) accord-
ing to the classical double disk test [13] and (2) Mueller–
–Hinton agar (Oxoid) with the addition of cloxacillin (Sig-
ma-Aldrich, St Louis, MO, USA) at a concentration of 250
μg/ml [15]. Klebsiella pneumoniae ATCC 700603 strain was
used as the ESBL producing control strain.
Assessment of drug-susceptibility. A broth microdilution
method was used to assess susceptibility to antibiotics [16].
The minimum inhibitory concentrations (MICs) were de-
termined within the range of 0.032–512 μg/ml for the fol-
lowing antibiotics: ampicillin/sulbactam (SAM), piperacil-
lin (PIP), piperacillin/tazobactam (TZP), ceftazidime
(CAZ), cefotaxime (CTX), cefepime (FEP), imipenem
(IMP), meropenem (MEM), tetracycline (TE), gentamicin
(GM), netilmicin (NET), amikacin (AN), and ciprofloxa-
cin (CIP). Escherichia coli ATCC 25922 and Escherichia coli
ATCC 35218 were used as reference strains. Following the
incubation period, the MIC values of the antibiotics being
studied were read for the Acinetobacter baumannii strains
and susceptibility was interpreted according to the criteria
established by the Clinical and Laboratory Standards Insti-
tute [17]. Drug-resistance phenotypes of the respective
strains were determined.
Genetic methods. Acinetobacter baumannii genomic DNA
was isolated using a Genomic Mini kit (A&A Biotechnolo-
gy, Poland). Genes were detected by the PCR technique.
The PCR reaction was conducted in the final volume of
25 μl assay mixture, containing 12.5 μl of 2 × PCR RED
(DNA-Gdansk, Poland), 3 μl of extracted DNA, and 10 pmol
of each of the starters (PERf 5’-AGTCAGCGGCTTAGA-
TA-3’; PERr 5’-CGTATGAAAAGGACAATC-3’ [18], in
a Cyclone 96 (PEQLAB Biotechnology GmbH, Germany)
following the procedure: 1 cycle at 94°C for 5 min; 35 cycles
at 94°C for 1 min, at 57°C for 1 min, at 72°C for 1 min; 1 cycle
at 72°C for 10 min [19]. PCR products were analyzed using
horizontal agarose gel electrophoresis (1.5%). The resultant
electrophoretic distributions — the expected amplification
product of 978 bp — were assessed in ultraviolet radiation
(UV) and then archived using the gel documentation system
ChemiDoc XRS (Bio-Rad, Hercules, CA, USA). Acinetobacter
baumannii LMG 1025 strain was used in the study as a control.
Results
A total of 51 Acinetobacter baumannii strains were
identified and examined. Most (78.0%) of these
strains were obtained from patients treated in the in-
tensive care unit. Approximately 75% of these strains
were isolated from samples collected from the respi-
ratory tract, mostly from bronchial secretion (52.9%).
The ESBL type b-lactamases were determined
based on phenotypic tests.  The minimum and diffi-
cult to interpret effects of inhibition zone extension
around the cephalosporin disks towards the inhibitor
were observed only in the test performed on Muel-
ler–Hinton agar with cloxacillin, which inhibits chro-
mosomal cephalosporinases that mask simultaneous
occurrence of ESBL. Despite an ambiguous ESBL
test pattern, approximately 20% of the strains can be
treated as positive.
However, molecular biology techniques (PCR),
which confirmed the presence of b-lactamase, failed
to show the blaPER-1 b-lactamase gene in any of the
Acinetobacter baumannii strains studied.
Figure 1 presents the overall susceptibility of
Acinetobacter baumannii strains to the antibiotics stud-
ied. Most strains were susceptible to meropenem
(76.5%), cefepime (60.8%) and ampicillin combined
with sulbactam (56.9%). At the same time, the low-
est levels of resistance were found with meropenem
and ampicillin with sulbactam (13.7%) and piperacil-
lin combined with tazobactam (17.6%). About 50%
of the strains were susceptible to netilmicin, which
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was the most active antibiotic among the aminogly-
cosides examined. A considerable percentage of the
strains showed intermediate susceptibility to piper-
acillin with tazobactam (66.7%). The highest level of
resistance was noted to piperacillin, tetracycline,
ciprofloxacin and cefotaxime.
The distribution of antibiotic MICs for Acineto-
bacter baumannii strains is presented in Table 1.
Among the most active antibiotics (meropenem,
cefepime, ampicillin/sulbactam), the commonest
MIC values were as follows: meropenem MIC = 4
μg/ml in 41.3%, cefepime MIC = 4 μg/ml in 23.5%,
and ampicillin/sulbactam MIC = 16 μg/ml in 29.4%
of the strains. In the group of the least active antibi-
otics, the commonest MIC values were: piperacillin
MIC ≥ 256 μg/ml in 62.7%, tetracycline MIC = 64
μg/ml in 21.6%, ciprofloxacin MIC = 16 μg/ml
in 49.0%, and cefotaxime MIC = 64 μg/ml in 29.4%
of the strains.
Based on the resistant strain category, phenotypes
of resistance were determined, of which the common-
est among Acinetobacter baumannii strains are shown
in Table 2. Most strains were resistant to six or seven
antibiotics (nine strains in each group), which in both
groups presented various resistance phenotypes. The
commonest profile of resistance was: PIPR, CAZR,
CTXR, TER, CIPR, which was observed in six strains.
No strain was found to be resistant to all the antibiot-
ics (13). Two A. baumannii isolates showed resistance
to the largest number of antibiotics (11), whereas
another two strains exhibited resistance only to tetra-
cycline and amikacin.
Discussion
The phenotypic tests used to detect extended spec-
trum b-lactamases in 51 Acinetobacter baumannii
strains indicate their potential occurrence in approx-
imately 20% of isolates. When compared to litera-
ture data, this percentage seems reasonable, and the
relatively high level may in most cases result from the
plasmid nature of the enzymes and a selective pres-
sure due to excessive use of antibiotics. Irrespective
of the family, extended spectrum b-lactamases have
been found in approximately 6.5–28% of isolates [20,
21]. Routine detection of Acinetobacter spp. strains
producing ESBL using phenotypic methods may be
difficult, because the effects of synergy between ceph-
alosporins and clavulanic acid, typically observed in
ESBL-positive rods of Enterobacteriaceae, can be
minimal [21].
The blaPER-1 gene is widespread in the strains of
Acinetobacter spp., P. aeruginosa, Salmonella enterica
serowar Typhimurium and Providencia rettgeri in Tur-
key [9, 22], in the region where PER-1 enzyme is
present even in 32% of Acinetobacter spp. and 55%
of P. aeruginosa [22]. A high prevalence of PER-1
positive Acinetobacter spp. strains has been observed
in Korea (54.6%) [11]. Although microorganisms with
PER-1 expression have been found to predominate
in Turkey, outbreaks induced by P. aeruginosa strains
have been reported from Italy [5], where PER-1 has
also been detected in P. mirabilis and Alcaligenes faeca-
lis [23, 24]. Likewise, the presence of this enzyme has
also been noted in France and Spain [25, 26]. PER-1
Figure 1. In vitro susceptibility of Acinetobacter baumannii strains (n = 51). SAM — ampicillin/sulbactam;
PIP — piperacillin; TZP — piperacillin/tazobactam; CAZ — ceftazidime; CTX — cefotaxime; FEP — cefepime;
IMI — imipenem; MEM — meropenem; TE — tetracycline; GM — gentamicin; NET — netilmicin; AN — amikacin;
CIP — ciprofloxacin; R — resistant; I — intermediate; S — susceptible
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Table 2. Commonest phenotypes of resistance to antibiotics among the strains of Acinetobacter baumannii
Resistance to Phenotypes of resistance to antibiotics Number
a definite number of strains
of antibiotics
11 PIPR TZPR CAZR CTXR FEPR IMIR MEMR TER GMR NETR CIPR 2
8 PIPR CTXR IMIR TER GMR NETR ANR CIPR 2
5 PIPR CAZR CTXR TER CIPR 6
4 PIPR CTXR TER CIPR 3
3 PIPR CTXR CIPR 2
2 TER ANR 2
PIP — piperacillin; TZP — piperacillin/tazobactam; CAZ — ceftazidime; CTX — cefotaxime; FEP — cefepime; IMI — imipenem;
MEM — meropenem; TE — tetracycline; GM — gentamicin; NET — netylmicin; AN — amikacin; CIP — ciprofloxacin; R — resistant
producing Acinetobacter baumannii has been reported
from France, Belgium, Romania, Russia and Hungary
[10, 19, 27–29]. Subsequent variants have been de-
scribed in the PER family in various bacteria (also in
A. baumannii), among which PER-2 is found to pre-
dominate in some South American countries [30, 31].
Most strains of A. baumannii with the blaPER-1 gene,
investigated in various countries, do not exhibit a con-
sanguineous relationship to one another, something
that is suggested by a clonal model of spread of this
mechanism of resistance [9, 11]. The analysis of the
blaPER-1 gene in various Gram-negative bacteria re-
vealed not only (in most cases) their chromosomal,
but also plasmid, location [32, 33]. These genes were
identified within transposon Tn1213 limited by two
insertion sequences ISPa12 and ISPa13, when they
had chromosomal location in P. aeruginosa, P. stuartii
and A. baumannii. Contrary to that, the PER-1 gene
carried on plasmids was not part of the above-men-
tioned transposon — only the ISPa12 sequence above
the blaPER-1 gene was identified. These plasmids have
been isolated from Salmonella enterica serowar Ty-
phimurium and A. baumannii. The relation between
blaPER-2 genes also with the ISPa12 sequence seems to
suggest a similar mechanism of gene mobilization on
separate continents (blaPER-2 in South America vs. bla-
PER-1 in Europe and Asia). In both cases, the expres-
sion of the blaPER-1 gene was controlled by the pro-
moter sequence located in ISPa12. It is interesting
that the blaPER-3 gene detected in the Aeromonas punc-
tata strain was combined with the ISCR1 element sit-
uated within class 1 integron In39. This finding may
indicate a different mode of blaPER gene spread.
In Poland, ESBLs are seldom detected in other
groups of bacteria (non-fermentative bacilli), apart
from the Enterobacteriaceae family. Initial reports on
PER-1 refer to P. aeruginosa strains [34], which, com-
pared to our findings, indicates a low involvement of
these enzymes in resistance to b-lactams in non-fer-
mentative bacilli. The appearance of PER b-lacta-
mases in new species of bacteria in various regions
suggests the continuous spread of resistance deter-
minants.
Conclusions
The application of phenotypic tests used to detect
ESBL showed a likely presence of this mechanism of
resistance in approximately 20% of Acinetobacter bau-
mannii strains. Our strains seem not to use ESBL
PER-1 as a determinant of resistance to b-lactam an-
tibiotics. The most active antibiotics against the strains
examined included meropenem, cefepim and ampi-
cillin with sulbactam.
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